GuideAI Health Corp. · NEO:GDAI

GuideAI Health — Investor Presentation (November 2026)

24 slides from GuideAI Health's investor presentation, Nov 20, 2026

  1. Slide 1: Improving Vascular Health with AI-driven Early Disease Detection

    I NVEST OR PRESE NTATI ON Improving Vascular Health with AI-driven Early Disease Detection & Surgical Precision 230 Million Patients. FDA-Cleared Triage AI. One Company. NO VEMBER 20 26 CBOE: GDAI FSE: ZN0

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Terms of Us e Forward-looking statements are based on management’s current expectations, assumptions, and beliefs regarding future events, including assumptions regarding: the availability of financing; successful and timely completion of development, validation and clinical studies

  3. Slide 3: Investment Highlights

    Investment Highlights $200B+ Peripheral Arterial Disease (PAD) Problem1 200+ Global Hospital LOIs Peripheral Arterial Disease (PAD) is widely underdiagnosed and contributes to LOIs from 200+ hospitals globally, representing a potential commercial pipeline more than $200B in annual healthcare costs i

  4. Slide 4: Peripheral Arterial Disease: 230 Million Patients, Routinely Missed

    THE P ROBLEM Peripheral Arterial Disease: 230 Million Patients, Routinely Missed 230M1 People with PAD globally 63%+2 of significant cardiovascular findings go unreported on routine CT 1M+3 Amputations annually — can be preventable PAD progresses silently. By the time it's detected, 1https://www.aha

  5. Slide 5: 50 CT Scans Per Day. 5 Images Per Second. Disease Gets Missed.

    ROOT C AU S E 50 CT Scans Per Day. 5 Images Per Second. Disease Gets Missed. Peripheral artery disease remains under- recognised and underdiagnosed, contributing to delayed diagnosis and poorer patient outcomes2 THE RA DIOLOGIST R EA LITY • A single CT scan = hundreds of individual images • Average

  6. Slide 6: Behind Every Missed Scan Is a Patient

    W HY IT M ATTE RS Behind Every Missed Scan Is a Patient WI T H O UT E A R L Y DE T E CT I ON WI TH G UI DEA I E ARL Y D ETECTI O N Silent disease progression AI can flag early vascular markers Critical limb ischemia Physicians bettered equipped to intervene early Amputation Potential to reduce amput

  7. Slide 7: Four Forces That Make This the Right Moment

    S TRU CTU RA L TAI L WI NDS Four Forces That Make This the Right Moment Diabetes Epidemic AI Imaging Market IDF projects 853M adults with diabetes by 2050 — $2.2B in 2026, forecast $17.8B by 2033 at 34.8% PAD's primary risk factor. Every new diagnosis is a Compound Annual Growth Rate (CAGR). Deep- p

  8. Slide 8: VascularAssist— Finding What Others Miss

    G UI DE AI HEA LT H S O L U T IO N VascularAssist— Finding What Others Miss No New Hardware AI-Powered Detection Actionable Output Designed to integrate with existing CT Deep learning trained on data from Structured, standardized reports. imaging infrastructure, with the goal 2,100+ hospitals. Mimic

  9. Slide 9: The Valuation Gap Is the Opportunity

    M AR KET OPP ORTUN ITY The Valuation Gap Is the Opportunity Addressable medical imaging AI market $6B2 (28% CAGR) 230M1 $20B3 Total AI in medical imaging by 2029 Patients with Peripheral Arterial Disease $233B+4 Annual US healthcare cost burden of PAD HeartFlow targets 200M coronary patients, valued

  10. Slide 10: Every Competitor Is in a Different Anatomy

    C OMP ETITI VE LA NDSC A PE Every Competitor Is in a Different Anatomy C om p any Foc us Area PA D C overag e Viz.ai Stroke / Brain None Aidoc Acute radiology triage None Cleerly Coronary arteries None HeartFlow Coronary arteries None G uid eA I H ealth P ER IP H ER A L V A S C U L A R FIR S T M O V

  11. Slide 11: A Proven Blueprint. An Unaddressed Market.

    THE I NVE STMEN T TH ESIS A Proven Blueprint. An Unaddressed Market. H EARTF L OW IN C. G UID E AI H EA LT H $176M Revenue 1 Early-Stage Opportunity (FY 2025) Targeting Multiple Vascular Diseases (Starting Built on AI + Coronary Imaging with Peripheral Arterial Disease) Multiple Advanced AI Models,

  12. Slide 12: Recurring SaaS Revenue That Compounds With Each Disease Area

    BUSINESS MODEL Recurring SaaS Revenue That Compounds With Each Disease Area Hospitals & Radiology Groups Executive Health Programs Buyer Hospital system or radiology group Preventive cardiology or executive physical program Sales cycle Procurement and IT integration Approximately eight weeks to laun

  13. Slide 13: A One-Time Implementation Fee Plus Recurring Per-Hospital Subscription

    BUSINESS MODEL · PRELIMINARY PRICING ASSUMPTIONS A One-Time Implementation Fee Plus Recurring Per-Hospital Subscription PUBLIC RA DIOLOGY-AI C ONTRACT BE NCHMA RKS 1 2 3 Publicly disclosed hospital contracts, annualized Implementation Fee VAOT Subscription Additional Modules ~US$35K / yr Viz.ai via

  14. Slide 14: One Scan. Every Artery Segment from Abdomen to Ankle.

    WHAT THE PROG RA M RETURNS One Scan. Every Artery Segment from Abdomen to Ankle. Every scan produces a structured, repeatable report, the foundation for recurring annual reads ST RU C TU RE D RE P ORT · P ER -SE GM E NT GR A DIN G Differentiated Gr ades every segm ent from mid-abd omen to ankle, ins

  15. Slide 15: A Faster Path to Revenue: The Executive Health

    EXECUTIVE HEALTH A Faster Path to Revenue: The Executive Health Plaque formation often begins in the lower extremities. GuideAI Health partners with preventive cardiology and executive health programs to analyze imaging they already acquire for peripheral arterial disease, which is often missed and

  16. Slide 16: Boone Heart Institute: Providing Clinical Validation

    FIRST EXECUTIVE HEALTH PA RTNER Boone Heart Institute: Providing Clinical Validation Signed September 2026. Boone Heart Institute, a preventive cardiology practice that performs executive physicals and vascular screening, is GuideAI’ s first executive health site, initially providing clinical valida

  17. Slide 17: LOIs from 200+ Hospitals. World-Class Data. Named Partners.

    VALIDATION & PARTNERSHIPS LOIs from 200+Hospitals. World-Class Data. Named Partners. vRadPartnership Advocate Health Preventive Medicine Boone Heart Exclusive access from vRad LOI Medicine Centers Institute to 1 billion+ medical images 69 hospitals. 6M patients Clinical validation studies Colorado p

  18. Slide 18: Five Near-Term Milestones

    NEA R-TERM CATALYSTS Five Near-Term Milestones 1 VAOT FDA 510(k) Clearance Commercial launch trigger Obtained 2 Clinical Validation of our Technology Proving use case in commercial capacity Launched 3 Hospital & Executive Health Clinics First revenue visibility Expected Q4 2026 4 VAPAD 510(k) FDA Cl

  19. Slide 19: FDA Clears GuideAI's AI Software for Vascular Disease

    V as c ul a rA ss i st O c cl u si on T r i a ge (VA O T ) | F DA 510 (k ) cl e a ra nc e | J une 202 6 FDA Clears GuideAI's AI Software for Vascular Disease The U.S. Fo o d an d Drug A d m inistration (FDA ) g ran ted 510(k ) clearan ce to G uid eA I H ealth for its 1 artificial intellig enc e so f

  20. Slide 20: How Well It Works and What It Means for GuideAI

    How Well It Works and What It Means for GuideAI How accurate it is (clinical How it fits into hospitals What it means for GuideAI performance testing) • In testing, VAOT correctly flagged • VAOT runs inside the imaging • This is a defining regulatory above 90% of patients who had systems hospitals a

  21. Slide 21: Three Moats That Are Hard to Replicate

    D EF ENS I BL E T ECH NO L O GY Three Moats That Are Hard to Replicate D AT A C LI NIC AL OR IG IN WO RK FL OW IN TE G RAT I ON Exclusive access to 1B+ images from Built by interventional radiologists Designed to plug into existing hospital 2,100+ hospitals via vRad. More data who saw the problem fi

  22. Slide 22: Building the Future of AI-Driven Vascular Disease Diagnosis & Treatment

    ROA DMAP TO COMMERCIALIZ ATION Building the Future of AI-Driven Vascular Disease Diagnosis & Treatment Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027 Achieved FDA 510(k) Launched pilot at the Perform pivotal study for Achieve FDA 510(k) EMR integration with clearance for first AI- Boone Heart Institute in

  23. Slide 23: Built by the Clinicians Who Saw What Was Being Missed

    THE T EAM Built by the Clinicians Who Saw What Was Being Missed GuideAI was founded by interventional radiologists who spent careers reviewing imaging and repeatedly seeing early PADgo undetected. That clinical insight drives everything. Raj Shah, MD MBA Luke Higgins, MD PhD Chief Executive Officer

  24. Slide 24: Thank you

    Thank you 230 Million Patients. FDA-Cleared Triage AI. One Company. CBOE: GDAI FSE: ZN0

GuideAI Health — Investor Presentation (November 2026) on 6ix